USP9X and cancer: From a mechanistic point of view, we identified down-regulation of Usp9X as well as Bag3 followed by enhanced Mcl-1-degradation as one of the driving mechanisms subjacent to the profound anti-cancer activity inherent to a combined inhibition of ERK signaling and Bcl-2/Bcl-xL.